1)Bryant HE, et al:Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose)polymerase. Nature 434:913-917, 2005
2)Farmer H, et al:Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434:917-921, 2005
3)Integrated genomic analyses of ovarian carcinoma. Nature 474:609-615, 2011
4)Pennington KP, et al:Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res 20:764-775, 2014
5)Ledermann J, et al:Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer:a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Lancet Oncol 15:852-861, 2014
6)Mirza MR, et al:Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer. N Engl J Med 375:2154-2164, 2016
7)Murai J, et al:Trapping of PARP1 and PARP2 by clinical PARP inhibitors. Cancer Res 72:5588-5599, 2012
8)Lord CJ, et al:PARP inhibitors:Synthetic lethality in the clinic. Science 355:1152-1158, 2017
9)Murai J, et al:Stereospecific PARP trapping by BMN 673 and comparison with olaparib and rucaparib. Mol Cancer Ther 13:433-443, 2014
10)Fong PC, et al:Inhibition of poly(ADP-ribose)polymerase in tumors from BRCA mutation carriers. N Engl J Med 361:123-134, 2009
11)Ledermann J, et al:Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med 366:1382-1392, 2012
12)Ledermann JA, et al:Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy:an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial. Lancet Oncol 17:1579-1589, 2016
13)Kaye SB, et al:Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly(ADP-ribose)polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer. J Clin Oncol 30:372-379, 2012
14)Pujade-Lauraine E, et al:Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation(SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol 18:1274-1284, 2017
15)Moore K, et al:Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer. N Engl J Med. 2018 Oct 21. doi:10.1056/NEJMoa1810858.(Epub ahead of print)PubMed PMID:30345884
16)Sandhu SK, et al:The poly(ADP-ribose)polymerase inhibitor niraparib(MK4827)in BRCA mutation carriers and patients with sporadic cancer:a phase 1 dose-escalation trial. Lancet Oncol 14:882-892, 2013
17)Swisher EM, et al:Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma(ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial. Lancet Oncol 18:75-87, 2017
18)Coleman RL, et al:Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy(ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 390:1949-1961, 2017
19)Coleman RL, et al:A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation - An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol 137:386-391, 2015
20)Shen Y, et al:BMN 673, a novel and highly potent PARP1/2 inhibitor for the treatment of human cancers with DNA repair deficiency. Clin Cancer Res 19:5003-5015, 2013
21)de Bono J, et al:Phase I, dose-escalation, two-part trial of the PARP inhibitor talazoparib in patients with advanced germline BRCA1/2 mutations and selected sporadic cancers. Cancer Discov 7:620-629, 2017
22)Litton JK, et al:Talazoparib in Patients with Advanced BreastCancer and a Germline BRCA Mutation. N Engl J Med 379:753-763, 2018
23)Oza AM, et al:Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer:a randomised phase 2 trial. Lancet Oncol 16:87-97, 2015
24)Kummar S, et al:Randomized trial of oral cyclophosphamide and veliparib in high-grade serous ovarian, primary peritoneal, or fallopian tube cancers, or BRCA-mutant ovarian cancer. Clin Cancer Res 21:1574-1582, 2015
25)Liu JF, et al:Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer:a randomised phase 2 study. Lancet Oncol 15:1207-1214, 2014
26)Huang J, et al:The PARP1 inhibitor BMN 673 exhibits immunoregulatory effects in a Brca1(-/-)murine model of ovarian cancer. Biochem Biophys Res Commun 463:551-556, 2015
27)Higuchi T, et al:CTLA-4 blockade synergizes therapeutically with PARP inhibition in BRCA1-deficient ovarian cancer. Cancer Immunol Res 3:1257-1268, 2015
28)Jiao S, et al:PARP inhibitor upregulates PD-L1 expression and enhances cancer-associated immunosuppression. Clin Cancer Res 23:3711-3720, 2017
29)Aoki D, et al:PARP inhibitors and quality of life in ovarian cancer.Lancet Oncol 19:1012-1014, 2018